KP-457

CAS No. 1365803-52-6

KP-457( —— )

Catalog No. M37116 CAS No. 1365803-52-6

KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 141 Get Quote
5MG 217 Get Quote
10MG 353 Get Quote
25MG 634 Get Quote
50MG 1003 Get Quote
100MG 1332 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    KP-457
  • Note
    Research use only, not for human use.
  • Brief Description
    KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).
  • Description
    KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    MMP
  • Recptor
    MMP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1365803-52-6
  • Formula Weight
    480.56
  • Molecular Formula
    C21H24N2O7S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(CS(=O)(=O)C1=CC=C(OCC#CC)C=C1)(N(C=O)O)C2=CC=C(CNS(C)(=O)=O)C=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Tanomastat

    Tanomastat (BAY 129566) is a potent,orally available, non-peptidic inhibitor of MMP-2, MMP-3 and MMP-9 with 11, 143 and 301 nM, respectively.

  • T-26c

    T-26c is highly potent and selective matrix metalloproteinase-13 (MMP-13) inhibitor (IC50: 6.75 pM).

  • MMP-7-IN-2

    MMP-7-IN-2 acts as a selective and potent MMP7 inhibitor and can be used to study inflammatory responses and vascular-related diseases.